Literature DB >> 25697040

[Pulmonary hypertension due to left heart diseases].

Jean-Luc Vachiéry, Yochai Adir, Joan Albert Barberà, Hunter Champion, John Gerard Coghlan, Vincent Cottin, Teresa De Marco, Nazzareno Galiè, Stefano Ghio, J Simon R Gibbs, Fernando Martinez, Marc Semigran, Gerald Simonneau, Athol Wells, Werner Seeger.   

Abstract

Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-LHD is unknown, a subset of patients might present significant PH that cannot be explained by a passive increase in left-sided filling pressures. The term "out-of-proportion" PH has been used to identify that population without a clear definition, which has been found less than ideal and created confusion. We propose a change in terminology and a new definition of PH due to LHD. We suggest to abandon "out-of-proportion" PH and to distinguish "isolated post-capillary PH" from "post-capillary PH with a pre-capillary component" on the basis of the pressure difference between diastolic pulmonary artery pressure and pulmonary artery wedge pressure. Although there is no validated treatment for PH-LHD, we provide insights into management and discuss completed and randomized trials in this condition. Finally, we provide recommendations for future clinical trials to establish safety and efficacy of novel compounds to target this area of unmet medical need. (J Am Coll Cardiol 2013;62:D100-8) ©2013 by the American College of Cardiology Foundation.

Entities:  

Year:  2014        PMID: 25697040

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  1 in total

1.  Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.

Authors:  Xiang Zhang; Xueming Zhang; Saihua Wang; Jun Luo; Zhihong Zhao; Changzhu Zheng; Jieyan Shen
Journal:  Can Respir J       Date:  2018-03-26       Impact factor: 2.409

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.